IMVT – immunovant, inc. (US:NASDAQ)

News

Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway [Yahoo! Finance]
Immunovant Q3 Earnings Call Highlights [Yahoo! Finance]
Immunovant GAAP EPS of -$0.61 beats by $0.10 [Seeking Alpha]
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com